A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer
Status: Recruiting
Location: See all (6) locations...
Study Type: Observational
SUMMARY
To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with gross hematuria.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age 18 years or older
• Have documented or reported gross hematuria within 3 month of study enrollment
• Willing and able to give written informed consent
Locations
United States
California
Cedars-Sinai Medical Center
RECRUITING
Los Angeles
University of California Los Angeles
RECRUITING
Los Angeles
New York
University of Rochester Medical Center
RECRUITING
Rochester
Texas
UT Southwestern Medical Center at Dallas
RECRUITING
Dallas
Other Locations
Japan
Department of Urology, Nara Medical University
RECRUITING
Nara
Nara Precfecture Seiwa Medical Center
RECRUITING
Nara
Contact Information
Primary
Charles Rosser, MD
charles.rosser@cshs.org
310-423-5609
Time Frame
Start Date: 2016-12-30
Estimated Completion Date: 2027-04-30
Participants
Target number of participants: 450
Authors
Related Therapeutic Areas
Sponsors
Collaborators: University of Rochester, Nara Prefecture Seiwa Medical Center, Nara Medical University, Fred Hutchinson Cancer Center, University of Texas, Nonagen Bioscience Corporation, National Cancer Institute (NCI), University of California, Los Angeles
Leads: Cedars-Sinai Medical Center